Belgian biopharmaceutical company UCB has acquired California-based Neurona Therapeutics, a firm specialising in epilepsy research, in a deal worth up to $1.15 billion.
Neurona Therapeutics focuses on cell therapies for neurological disorders, particularly its investigational treatment NRTX-1001. This therapy, currently undergoing phase I/II clinical trials, has shown promising preliminary results.
The deal includes an initial payment of $650 million, with potential milestone payments totalling up to $500 million. UCB stated that the acquisition will not affect its revenue forecasts for 2026.
Epilepsy treatments are already a key area of expertise for UCB, which has a portfolio of therapies addressing this neurological condition.
